In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.
In this video, Jennifer A. Woyach, MD, discusses results from the AMPLIFY trial, presented at ASH Annual Meeting and Exhibition.The trial evaluated fixed-duration acalabrutinib (Calquence, AstraZeneca ...
In this video, Jennifer A. Woyach, MD, discusses a phase 3 randomized trial comparing pirtobrutinib to idelalisib or bendamustine plus rituximab for chronic lymphocytic leukemia pretreated with Bruton ...
Expert Rev Hematol. 2013;6(4):441-449. In conclusion, although age should generally determine the goal of treatment in CLL, the patient's functional status rather than chronological age can be ...
China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...
Cells treated with ibrutinib and acalabrutinib each had a unique set of 13 m/z signals, which opens up the possibility of studying these metabolites as biomarkers of therapeutic response.
During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...
Sleep apnea typically cannot be cured, but the condition is treatable and manageable. Treatment might include lifestyle changes, oral appliances, positive airway pressure, adaptive ventilation devices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback